High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide Cases

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 3, 2010, Pages 354-359

  Zackrisson, A L ^a   Lindblom, B ^a   Ahlner, J ^a  

^a DEPARTMENT OF FORENSIC GENETICS AND FORENSIC TOXICOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6;

ARTICLE; CAUSE OF DEATH; DRUG INTOXICATION; GENE DUPLICATION; GENE FREQUENCY; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; SUICIDE;

ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; CAUSE OF DEATH; CYTOCHROME P-450 CYP2D6; FEMALE; GENE DUPLICATION; HUMANS; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SUICIDE; SWEDEN; YOUNG ADULT;

EID: 77955865554     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.216     Document Type: Article

References (35)

1. Jönsson, A.K., Holmgren, P., Druid, H. & Ahlner, J. Cause of death and drug use pattern in deceased drug addicts in sweden, 2002-2003. Forensic Sci. Int. 169, 101-107 (2007).
2. Bertilsson, L. et al. Pronounced diferences between native Chinese and swedish populations in the polymorphic hydroxylations of debrisoquin and s-mephenytoin. Clin. Pharmacol. Ther. 51, 388-397 (1992).
3. Marez, D. et al. Polymorphism of the cytochrome p450 CYp2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7, 193-202 (1997).
4. Sachse, C., Brockmöller, J., Bauer, S. & Roots, I. Cytochrome p450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284-295 (1997).
5. Sachse, C., Brockmoller, J., Hildebrand, M., Muller, K. & Roots, I. Correctness of prediction of the CYp2D6 phenotype confrmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics 8, 181-185 (1998).
6. Dahl, M.L., Johansson, I., Palmertz, M.P., Ingelman-sundberg, M. & Sjöqvist, F. Analysis of the CYp2D6 gene in relation to debrisoquin and desipramine hydroxylation in a swedish population. Clin. Pharmacol. Ther. 51, 12-17 (1992).
7. Dahl, M.L., Johansson, I., Bertilsson, L., Ingelman-sundberg, M. & Sjöqvist, F. Ultrarapid hydroxylation of debrisoquine in a swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 274, 516-520 (1995).
8. Bertilsson, L. et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341, 63 (1993).
9. Stamer, U.M., Stuber, F., Muders, T. & Musshof, F. Respiratory depression with tramadol in a patient with renal impairment and CYp2D6 gene duplication. Anesth. Analg. 107, 926-929 (2008).
10. Kirchheiner, J., Keulen, J.T., Bauer, S., Roots, I. & Brockmoller, J. Efects of the CYp2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J. Clin. Psychopharmacol. 28, 78-83 (2008).
11. Voronov, P., Przybylo, H.J. & Jagannathan, N. Apnea in a child after oral codeine: a genetic variant-an ultra-rapid metabolizer. Paediatr. Anaesth. 17, 684-687 (2007).
12. Brosen, K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther. Drug Monit. 18, 393-396 (1996).
13. Güzey, C., Norström, A. & Spigset, O. Change from the CYp2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther. Drug Monit. 24, 436-437 (2002).
14. Laine, K. et al. Inhibition of cytochrome p4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin. Pharmacol. Ther. 70, 327-335 (2001).
15. Chang, M., Dahl, M.L., Tybring, G., Gotharson, E. & Bertilsson, L. Use of omeprazole as a probe drug for CYp2C19 phenotype in swedish Caucasians: comparison with s-mephenytoin hydroxylation phenotype and CYp2C19 genotype. Pharmacogenetics 5, 358-363 (1995).
16. Alvan, G., Bechtel, P., Iselius, L. & Gundert-Remy, U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 39, 533-537 (1990).
17. Sim, S.C. et al. A common novel CYp2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79, 103-113 (2006).
18. Zackrisson, A.L., Holmgren, P., Gladh, A.B., Ahlner, J. & Lindblom, B. Fatal intoxication cases: cytochrome p450 2D6 and 2C19 genotype distributions. Eur. J. Clin. Pharmacol. 60, 547-552 (2004).
19. Kawanishi, C., Lundgren, S, Agren, H. & Bertilsson, L. Increased incidence of CYp2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur. J. Clin. Pharmacol. 59, 803-807 (2004).
20. Bertilsson, L., Alm, C., De Las Carreras, C., Widen, J., Edman, G. & Schalling, D. Debrisoquine hydroxylation polymorphism and personality. Lancet 1, 555 (1989).
21. Llerena, A., Edman, G., Cobaleda, J., Benitez, J., Schalling, D. & Bertilsson, L. Relationship between personality and debrisoquine hydroxylation capacity. suggestion of an endogenous neuroactive substrate or product of the cytochrome p4502D6. Acta Psychiatr. Scand. 87, 23-28 (1993).
22. Gan, S.H., Ismail, R., Wan Adnan, W.A., Zulmi, W., Kumaraswamy, N. & Larmie, E.T. Relationship between type A and B personality and debrisoquine hydroxylation capacity. Br. J. Clin. Pharmacol. 57, 785-789 (2004).
23. Roberts, R.L., Luty, S.E., Mulder, R.T., Joyce, P.R. & Kennedy, M.A. Association between cytochrome p450 2D6 genotype and harm avoidance. Am. J. Med. Genet. B Neuropsychiatr. Genet. 127, 90-93 (2004).
24. González, I., Peñas-Lledó, E.M., Pérez, B., Dorado, P., Alvarez, M. & LLerena, A. Relation between CYp2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 9, 833-840 (2008).
25. Suzuki, E., Kitao, Y., Ono, Y., Iijima, Y. & Inada, T. Cytochrome p450 2D6 polymorphism and character traits. Psychiatr. Genet. 13, 111-113 (2003).
26. Kirchheiner, J., Lang, U., Stamm, T., Sander, T. & Gallinat, J. Association of CYp2D6 genotypes and personality traits in healthy individuals. J. Clin. Psychopharmacol. 26, 440-442 (2006).
27. Siegle, I., Fritz, P., Eckhardt, K., Zanger, U.M. & Eichelbaum, M. Cellular localization and regional distribution of CYp2D6 mRN and protein expression in human brain. Pharmacogenetics 11, 237-245 (2001).
28. Chinta, S.J., Pai, H.V., Upadhya, S.C., Boyd, M.R. & Ravindranath, V. Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome p4502D in human brain. Brain Res. Mol. Brain Res. 103, 49-61 (2002).
29. Hiroi, T., Kishimoto, W., Chow, T., Imaoka, S., Igarashi, T. & Funae, Y. Progesterone oxidation by cytochrome p450 2D isoforms in the brain. Endocrinology 142, 3901-3908 (2001).
30. Niwa, T. et al. Efect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYp2D6. Brain Res. Mol. Brain Res. 129, 117-123 (2004).
31. Yu, A.M., Idle, J.R. & Gonzalez, F.J. polymorphic cytochrome p450 2D6: humanized mouse model and endogenous substrates. Drug Metab. Rev. 36, 243-277 (2004).
32. Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F. & Ingelman-sundberg, M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYp2D6 alleles. J. Pharmacol. Exp. Ther. 278, 441-446 (1996).
33. Zackrisson, A.L. & Lindblom, B. Identifcation of CYp2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing. Eur. J. Clin. Pharmacol. 59, 521-526 (2003).
34. Söderbäck, E., Zackrisson, A.L., Lindblom, B. & Alderborn, A. Determination of CYp2D6 gene copy number by pyrosequencing. Clin. Chem. 51, 522-531 (2005).
35. Eriksson, S., Berg, L.M., Wadelius, M. & Alderborn, A. Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology. Assay Drug Dev. Technol. 1, 49-59 (2002).